{{Rsnum
|rsid=13035033
|Gene=MYO3B
|Chromosome=2
|position=170475778
|Orientation=plus
|GMAF=0.1442
|Gene_s=MYO3B
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 53.1 | 39.8 | 7.1
| HCB | 81.0 | 18.2 | 0.7
| JPT | 83.2 | 16.8 | 0.0
| YRI | 100.0 | 0.0 | 0.0
| ASW | 94.7 | 5.3 | 0.0
| CHB | 81.0 | 18.2 | 0.7
| CHD | 78.9 | 20.2 | 0.9
| GIH | 70.1 | 27.8 | 2.1
| LWK | 0.0 | 0.0 | 0.0
| MEX | 67.2 | 32.8 | 0.0
| MKK | 88.5 | 10.9 | 0.6
| TSI | 59.8 | 37.3 | 2.9
| HapMapRevision=28
}}{{PMID Auto
|PMID=23376709
|Title=A Two-Stage Genome-Wide Association Study to Identify Single Nucleotide Polymorphisms Associated with Development of Urinary Symptoms Following Radiotherapy for Prostate Cancer
}}

{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA}}